DataMeds AI settles debt litigation, cuts $19 million in liabilities

DataMeds AI said Thursday it settled litigation tied to a 2023 agreement, removing about $19 million in liabilities from its balance sheet and retiring 364,099 common shares. The company paid $450,000 in cash, a move that simplifies the capital structure as it pursues its healthcare platform strategy.

Why it matters: - The settlement removes roughly $19 million in liabilities from DataMeds AI's balance sheet. - The deal also retires about 364,099 common shares, reducing outstanding equity tied to the dispute. - The cash cost was $450,000, far below the liabilities previously carried. - The cleanup may give DataMeds AI more room to focus on operations and planned growth initiatives.

What happened: - DataMeds AI said it settled litigation tied to debt and receivables connected to the May 11, 2023 Wellgistics, LLC Membership Purchase Interest Agreement. - The liabilities had been carried on the company's balance sheet at about $19 million. - The company retired approximately 364,099 shares of DataMeds AI common stock as part of the settlement. - DataMeds AI paid $450,000 in cash for the agreement. - Interim Co-CEO Gerald E. Commissiong said the company was pleased to resolve the litigation and focus on healthcare delivery and compliant tokenization of pharmaceutical supply tracking and patient data.

The details: - DataMeds AI trades on Nasdaq under the ticker MEDS. - The company operates as a healthcare and Health IT business built around its EinsteinRx™ artificial intelligence platform and PharmacyChain™ smart contracts platform. - DataMeds AI said the settlement information is available in a Form 8-K filing with the Securities and Exchange Commission: the SEC filing. - DataMeds AI is also a B2i Digital Featured Company. - The company's profile is available here: the company's profile.

Between the lines: - The settlement closes a legal overhang that had been weighing on the company's financial presentation. - The large gap between the $19 million in liabilities and the $450,000 cash payment suggests the dispute was resolved on highly favorable financial terms for DataMeds AI. - The share retirement may also help simplify the company's capitalization as it works to maintain Nasdaq compliance and pursue future transactions. - The announcement highlights how much of DataMeds AI's strategy is tied to combining healthcare delivery, software and data-related infrastructure.

What's next: - DataMeds AI said it plans to keep building around telemedicine, diagnostic laboratory services and related healthcare technology. - The company also pointed to a proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors. - DataMeds AI's forward-looking plans include expanding EinsteinRx AI, PharmacyChain and Health Lives Here. - The company also said it aims to integrate telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies.

The bottom line: - DataMeds AI has turned a costly legal dispute into a small cash settlement, erased a large liability from its books and retired shares in the process.